A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery (POINTER)
A Phase 2b, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Dose-Finding Study to Evaluate the Efficacy on Renal Function and Safety of RMC-035 in Participants at High Risk for Kidney Injury Following Open-Chest Cardiac Surgery
Sponsor: Guard Therapeutics AB
Listed as NCT06475274, this PHASE2 trial focuses on Kidney Injury Following Open-Chest Cardiac Surgery and remains completed. Sponsored by Guard Therapeutics AB, it has been updated 9 times since 2024, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2024 — Jul 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Guard Therapeutics AB
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Córdoba, Spain , Dresden, Germany , Essen, Germany , Giessen, Germany , Halle, Germany , Hradec Králové, Czechia , Madrid, Spain , Montreal, Canada , München, Germany and 7 more locations